United TherapeuticsUTHR
Recorded

United Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Roger SongAnalyst

All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference. My name is Roger Song, covering analyst for SMID-cap Biotech in the U.S. It is my pleasure to have the fireside chat with United Therapeutics. We have the CFO, James Edgemond, and we also have investor relations, Harry Silvers.

James EdgemondCFO

Welcome, gentlemen. Great, Roger. Thanks for having us.

James EdgemondCFO

I'm going to turn it over to Harry real quick to do a forward-looking statement.

Harry SilversHead of Investor Relations and Senior Manager

Sorry, just to check the box here. Today we may make some forward-looking statements, so for any risks and uncertainties associated with those statements, please refer to our latest filings on Forms 10-K and 10-Q. Now back to James. Great.

James EdgemondCFO

Again, Roger, thanks for having Harry and I. We actually have Dr. Betsy Eades here, who does corporate development for United Therapeutics, with us today. Again, appreciate you hosting United Therapeutics. Overall, Roger, just a couple words just to start. Overall, we're very proud of what United Therapeutics and all the Unitherians have been doing during and across the third quarter that we recently reported. From a commercial standpoint, it's fair to say that the commercial strategy and the base business is working very well. We reported the highest revenue ever total for the organization at $833 million, and within that, TYVASO reported its highest revenue ever of $504 million. Again, the base business we think is working well. The commercial strategy is working well.

James EdgemondCFO

On the development side, during the quarter and the updates, it is going to be a very busy 2027. The FDA did accept the sNDA to use nebulized TYVASO in idiopathic pulmonary fibrosis that has a PDUFA date of April 26th. The FDA accepted the NDA for ralinepag for use in PAH as the only once-a-day oral prostacyclin that has a PDUFA date in June 24th. We fully enrolled and we are going to unblind in the second half of 2027, the TETON clinical study for progressive pulmonary fibrosis, so PPF, that has a very large patient population, and we will unblind that in the second half of 2027. In addition to the myriad and numerous research projects that Martine has going on within the organization to continue to provide the best patient care possible. Thanks for the opening and giving us a chance to have a word.

Roger SongAnalyst

Absolutely. All right. Maybe we focus on the base commercial business for a moment, TYVASO, and then particularly for PH-ILD. You recently have a very big win on the patent side, and then you can now have exclusive kind of rights for the PH-ILD side. Your core Q3 is pretty clean, right? Record referral in October as well. How should we think about Q4 and then into 2027, particularly the split between the PH-ILD versus PH? How much growth are we going to see in the PH-ILD side?

James EdgemondCFO

Yeah. Thank you, Roger. On the PH-ILD side, which is a main growth driver, and it will be for us as we look forward going forward. In general, if you were to go back to Q2, what Michael Benkowitz talked about coming out of the quarter was strength in the starts and the referrals. You saw that across Q3 in terms of really patient demand that drove this revenue growth. Michael also mentioned in the earnings call in October, we had the highest number of referrals across our commercial portfolio of over 1,000 referrals in the month of October, which is the highest record ever for us in referral basis. I think that goes to further demonstrate the base business and the commercial strategy is working well.

James EdgemondCFO

One aspect of your question is during this calendar year, Michael hired additional sales teams that will eventually transition to support the IPF launch. Those sales teams were in the field further educating physicians, talking about more on the PH-ILD side. We are not commercially promoting on the IPF side yet. You are seeing those relationships develop, and where I think you are going to see the benefit of those additional sales teams is in Q4 and across 2027. I think they will be in chair, and they will really start to have an impact. The Q3 was really momentum coming out of Q2 that demonstrated Q3 with a strong revenue performance.

Roger SongAnalyst

How should we think about the lead time from the referral to the revenue booking? How should we say about that?

James EdgemondCFO

Yeah. Thanks, Roger. With the settlement going forward, there's various things that will be done in terms of communicating to physicians regarding the transition of patients that were on another therapy to another form. So from a Liquidia product to TYVASO DPI or another therapy in the TYVASO DPI space. There's certain things there that are happening, and there will be a label amendment, which I think will give us kind of unfettered access to these PH-ILD patients on a going-forward basis. Naive patients coming in or being diagnosed with PH-ILD would transition, we believe, on the TYVASO DPI going forward as an effective therapy. I think you would start to see that momentum in Q4 and going into 2027 for the naive patients that are new to therapy.

Roger SongAnalyst

Mm-hmm. Okay. How about the switcher? I believe you said, in the beginning, at least in the near term, the modest switching.

Roger SongAnalyst

As they amend the label without the PH-ILD anymore, they cannot promote from day one, and the payer may react to the new label. So how should we think about the future switching kind of dynamic?

James EdgemondCFO

Yeah, correct. When Liquidia would update their label to remove the PH-ILD indication from their label, and you think about TYVASO DPI, that would be an effective therapy for these newly diagnosed patients to go straight on.

James EdgemondCFO

Yeah. Again, then from a payer perspective, once the label is updated, that would make its way through the payer platforms in terms of a reimbursement perspective.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day